Seres Therapeutics Stock Today
| MCRB Stock | USD 0.73 0.08 9.65% |
Performance0 of 100
| Odds Of DistressOver 76
|
Seres Therapeutics is trading at 0.7318 as of the 21st of November 2024, a 9.65 percent decrease since the beginning of the trading day. The stock's open price was 0.81. Seres Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Seres Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 22nd of October 2024 and ending today, the 21st of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 26th of June 2015 | Category Healthcare | Classification Health Care |
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. The company has 170.74 M outstanding shares of which 17.85 M shares are now shorted by private and institutional investors with about 5.75 trading days to cover. More on Seres Therapeutics
Moving together with Seres Stock
Moving against Seres Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Seres Stock Highlights
| CEO President | Eric MBA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Pharmaceutical Products (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Pharmaceutical Products, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsSeres Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Seres Therapeutics' financial leverage. It provides some insight into what part of Seres Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Seres Therapeutics (MCRB) is traded on NASDAQ Exchange in USA. It is located in 101 Cambridgepark Drive, Cambridge, MA, United States, 02140 and employs 233 people. Seres Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 138.96 M. Seres Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 170.74 M outstanding shares of which 17.85 M shares are now shorted by private and institutional investors with about 5.75 trading days to cover.
Seres Therapeutics currently holds about 195.8 M in cash with (117.35 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.58, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Seres Therapeutics Probability Of Bankruptcy
Ownership AllocationSeres Therapeutics shows a total of 170.74 Million outstanding shares. 30% of Seres Therapeutics outstanding shares are owned by institutional holders. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Seres Ownership Details
Seres Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Goldman Sachs Group Inc | 2024-06-30 | 667 K | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 342.2 K | |
| Lion Point Capital, Lp | 2024-09-30 | 340.8 K | |
| State Street Corp | 2024-06-30 | 339.5 K | |
| Verition Fund Managegment, Llc | 2024-06-30 | 314.2 K | |
| Pennant Investors Lp | 2024-06-30 | 292.3 K | |
| T. Rowe Price Associates, Inc. | 2024-06-30 | 267.4 K | |
| Northern Trust Corp | 2024-09-30 | 218.2 K | |
| Ubs Group Ag | 2024-06-30 | 200.7 K | |
| Flagship Ventures Management, Inc. | 2024-06-30 | 23.1 M | |
| Fmr Inc | 2024-09-30 | 22.9 M |
Seres Therapeutics Historical Income Statement
Seres Stock Against Markets
Seres Therapeutics Corporate Management
| Jeff York | VP HR | Profile | |
| Carlo Tanzi | Head of Investor Relations and Corporate Communications | Profile | |
| SPHR SHRMSCP | Executive Officer | Profile | |
| RPh Young | Executive Officer | Profile | |
| Kristin Ainsworth | Sr Communications | Profile | |
| JD Esq | Executive Officer | Profile | |
| David Ege | Executive Officer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Seres Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Seres Stock refer to our How to Trade Seres Stock guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Seres Therapeutics. If investors know Seres will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Seres Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.40) | Revenue Per Share 0.871 | Quarterly Revenue Growth (0.93) | Return On Assets (0.1) | Return On Equity (15.56) |
The market value of Seres Therapeutics is measured differently than its book value, which is the value of Seres that is recorded on the company's balance sheet. Investors also form their own opinion of Seres Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Seres Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Seres Therapeutics' market value can be influenced by many factors that don't directly affect Seres Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Seres Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Seres Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Seres Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.